Chronic lymphocytic leukemia (CLL) treatment is experiencing a shift away from chemotherapy in favor of novel agents. FCR chemotherapy, however, has shown impressive responses, and even curative effects in young patients, especially those with IGHV mutations. In this video, recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Matthew Davids, MD, MSc, of the Dana-Farber Cancer Institute, Boston, MA, speaks about a study combining novel agent duvelisib with FCR in young CLL patients (dFCR; NCT02158091). Dr Davids discusses the rationale behind the study, and the toxicities experienced. Finally, he points out the dramatic efficacy rates, with ~75% of patients reaching MRD negativity, including patients without IGHV mutations.